The Women's Health Initiative (WHI), published in 2002, was a large randomized trial in postmenopausal women averaging 63 years old, most of them well past menopause, testing a specific combination (oral conjugated equine estrogen plus a synthetic progestin).
It found small increases in relative risk for several outcomes, but the absolute numbers were modest: about 7 more heart-disease events, 8 more strokes, and 8 more breast cancers per 10,000 women per year, against 6 fewer colorectal cancers and 5 fewer hip fractures, with no change in overall death rate. A separate arm using estrogen alone (in women without a uterus) showed no increase in heart disease and, in longer follow-up, fewer breast cancers. The formulation tested is not the one most commonly prescribed today, and applying the average results from a 63-year-old study population directly to a 51-year-old with hot flashes is a common but real misreading of the data.
The debate isn't over the numbers themselves, which are well documented, but over how to use a 2002 trial in older women to counsel a newly menopausal woman today. Two opposite errors circulate: applying the older-population results to younger women, and dismissing the WHI entirely because 'those drugs aren't used anymore.'
What the research shows, and which source each finding rests on
WHI 2002 (CEE+MPA, mean age 63): CHD HR 1.29, breast cancer HR 1.26, stroke HR 1.41, pulmonary embolism HR 2.13, colorectal cancer HR 0.63, hip fracture HR 0.66. In absolute terms: 7 more CHD events, 8 more strokes, 8 more PEs, 8 more breast cancers per 10,000 person-years, against 6 fewer colorectal cancers and 5 fewer hip fractures. All-cause mortality unaffected (HR 0.98).
WHI estrogen-alone trial (hysterectomized women): CHD HR 0.91 (no increase); breast cancer HR 0.77, later a significant reduction in cumulative follow-up (HR 0.79, 0.65-0.97).
Mean WHI age was 63, and only about 30% of Cochrane-pooled participants were aged 50-59; many were more than a decade past menopause, meaning the trial's average results describe an older population than a newly menopausal woman.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Extrapolating WHI results to younger, newly menopausal women is a mistake
a caution flagged directly in the source material
The trial's average participant was 63 and many were over a decade past menopause; applying those hazard ratios to a 51-year-old with hot flashes describes a different population and a different risk-benefit balance than the one actually studied.
Dismissing WHI entirely because 'those drugs aren't used anymore' goes too far
a mirror-image caution flagged in the same source material
Route and progestogen differences between the WHI formulation and modern regimens are real, but no hard-endpoint randomized trial has ever tested transdermal estradiol plus micronized progesterone for cardiovascular outcomes, so claims that modern regimens simply 'don't increase heart disease' extrapolate from observational and pharmacology data rather than a demonstrated trial result.
What would settle it: A modern-regimen trial with hard cardiovascular endpoints in recently menopausal women, the same missing trial described throughout this topic.
What is really going on here
- Am I being quoted a relative risk or an absolute risk - how many women per 1,000 per year does that actually mean?
- Does that study apply to someone my age and distance from menopause, or was it done in women 10-20 years older?
- Which regimen was studied - oral CEE with MPA, or transdermal estradiol with micronized progesterone - and which am I being prescribed?
Questions for your doctor
- Which specific hormone and route was used in the study you're citing, and is it the same as what you're prescribing me?
- What is the absolute risk difference in events per 1,000 women, not just the relative risk?
- How does my age and years since menopause change how relevant that study is to me?
Questions with no answer yet
Would the same trial, run today with a modern transdermal estradiol and micronized progesterone regimen instead of the older oral formulation, produce a different balance of risks and benefits?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: No hard-endpoint randomized trial has ever tested transdermal estradiol plus micronized progesterone against placebo the way the original trial tested its specific oral formulation. Claims that the modern regimen is simply safer rest on route and progestogen-type observational data and pharmacology, not on a repeat of the original trial design.
What would test it: A modern-regimen trial with hard cardiovascular, breast cancer, and other endpoints in recently menopausal women, essentially a repeat of the original trial using today's most commonly prescribed formulation.
How would the trial's results have differed if the average participant had been 51 rather than 63 at enrollment?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: Only about 30 percent of the pooled trial population was aged 50-59, so the trial as run cannot directly answer what its own hazard ratios would have looked like in a population centered on the age most women actually start hormone therapy today. Age-stratified subgroup analyses exist but are not the same as a trial designed and powered around that younger population.
What would test it: A dedicated trial enrolling only women in their early 50s at or near the time of menopause, rather than a subgroup analysis carved out of a trial designed around an older population.
Sources
- 1.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the WHI randomized controlled trial. JAMA. 2002;288(3):321-33. · Randomised trial
- 2.Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the WHI randomized controlled trial. JAMA. 2004;291(14):1701-12. · Randomised trial
- 3.Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.Manson JE, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the WHI randomized trials. JAMA. 2013;310(13):1353-68. · Randomised trial
- 4.Long-term hormone therapy for perimenopausal and postmenopausal women.Marjoribanks J, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1:CD004143. · Systematic review or guideline
- 5.Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies (QResearch/CPRD). BMJ. 2019;364:k4810. · Observational study
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- Does hormone therapy really protect my bones and lower my risk of fractures?
- Can hormone therapy protect my heart, or does it increase my risk of heart disease?
- Does it matter how soon after menopause I start hormone therapy - is there a 'window of opportunity'?
- Will taking hormone therapy help me live longer?
- Is one type of hormone therapy safer than another - does it matter if I take a pill versus a patch or gel?
- Can hormone therapy lower my risk of type 2 diabetes or help with metabolism?
- Back to topic: Hormone therapy, heart, bone and longevity